{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31836816", "DateCompleted": {"Year": "2020", "Month": "12", "Day": "04"}, "DateRevised": {"Year": "2021", "Month": "01", "Day": "10"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "12", "Day": "13"}], "Language": ["eng"], "ELocationID": ["19107", "10.1038/s41598-019-55710-w"], "Journal": {"ISSN": "2045-2322", "JournalIssue": {"Volume": "9", "Issue": "1", "PubDate": {"Year": "2019", "Month": "Dec", "Day": "13"}}, "Title": "Scientific reports", "ISOAbbreviation": "Sci Rep"}, "ArticleTitle": "Molecular stratification within triple-negative breast cancer subtypes.", "Pagination": {"StartPage": "19107", "MedlinePgn": "19107"}, "Abstract": {"AbstractText": ["Triple-negative breast cancer (TNBC) has been subdivided into six distinct subgroups: basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), mesenchymal stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR). We recently identified a subgroup of TNBC with loss of the tumor suppressor PTEN and five specific microRNAs that exhibits exceedingly poor clinical outcome and contains TP53 mutation, RB1 loss and high MYC and WNT signalling. Here, show that these PTEN-low/miRNA-low lesions cluster with BL1 TNBC. These tumors exhibited high RhoA signalling and were significantly stratified on the basis of PTEN-low/RhoA-signalling-high with hazard ratios (HRs) of 8.2 (P\u2009=\u20090.0009) and 4.87 (P\u2009=\u20090.033) in training and test cohorts, respectively. For BL2 TNBC, we identified AKT1 copy gain/high mRNA expression as surrogate for poor prognosis (HR\u2009=\u20093.9; P\u2009=\u20090.02 and HR\u2009=\u20096.1; P\u2009=\u20090.0032). In IM, programmed cell death 1 (PD1) was elevated and predictive of poor prognosis (HR\u2009=\u20095.3; P\u2009=\u20090.01 and HR\u2009=\u20093.5; P\u2009<\u20090.004). Additional alterations, albeit without prognostic power, characterized each subtype including high E2F2 and TGF\u03b2 signalling and CXCL8 expression in BL2, high IFN\u03b1 and IFN\u03b3 signalling and CTLA4 expression in IM, and high EGFR signalling in MSL, and may be targeted for therapy. This study identified PTEN-low/RhoA-signalling-high, and high AKT1 and PD1 expression as potent prognostications for BL1, BL2 and IM subtypes with survival differences of over 14, 2.75 and 10.5 years, respectively. This intrinsic heterogeneity could be exploited to prioritize patients for precision medicine."]}, "AuthorList": [{"Identifier": ["0000-0002-5434-287X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute, University Health Network, 67 College Street, Toronto, Ontario, M5G 2M1, Canada."}], "LastName": "Wang", "ForeName": "Dong-Yu", "Initials": "DY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute, University Health Network, 67 College Street, Toronto, Ontario, M5G 2M1, Canada."}], "LastName": "Jiang", "ForeName": "Zhe", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Key laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academic of Sciences, Guiyang, Guizhou, 550014, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550025, China."}], "LastName": "Ben-David", "ForeName": "Yaacov", "Initials": "Y"}, {"Identifier": ["0000-0003-3731-5797"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Lunenfeld-Tanenbaum Research Institute, Sinai Health System, 600 University Avenue, Toronto, ON, Canada."}], "LastName": "Woodgett", "ForeName": "James R", "Initials": "JR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute, University Health Network, 67 College Street, Toronto, Ontario, M5G 2M1, Canada. eldad.zacksenhaus@utoronto.ca."}, {"Identifier": [], "Affiliation": "Department of Medicine, University of Toronto, Toronto, Ontario, Canada. eldad.zacksenhaus@utoronto.ca."}], "LastName": "Zacksenhaus", "ForeName": "Eldad", "Initials": "E"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Sci Rep", "NlmUniqueID": "101563288", "ISSNLinking": "2045-2322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "AR protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "MYC protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "MicroRNAs"}, {"RegistryNumber": "0", "NameOfSubstance": "Proto-Oncogene Proteins c-myc"}, {"RegistryNumber": "0", "NameOfSubstance": "RB1 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Androgen"}, {"RegistryNumber": "0", "NameOfSubstance": "Retinoblastoma Binding Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "TP53 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Suppressor Protein p53"}, {"RegistryNumber": "0", "NameOfSubstance": "Wnt Proteins"}, {"RegistryNumber": "EC 2.3.2.27", "NameOfSubstance": "Ubiquitin-Protein Ligases"}, {"RegistryNumber": "EC 3.1.3.67", "NameOfSubstance": "PTEN Phosphohydrolase"}, {"RegistryNumber": "EC 3.1.3.67", "NameOfSubstance": "PTEN protein, human"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Cluster Analysis"}, {"QualifierName": [], "DescriptorName": "Computational Biology"}, {"QualifierName": [], "DescriptorName": "Databases, Factual"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Gene Dosage"}, {"QualifierName": [], "DescriptorName": "Gene Expression Profiling"}, {"QualifierName": [], "DescriptorName": "Gene Expression Regulation, Neoplastic"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["metabolism"], "DescriptorName": "MicroRNAs"}, {"QualifierName": ["metabolism"], "DescriptorName": "PTEN Phosphohydrolase"}, {"QualifierName": [], "DescriptorName": "Prognosis"}, {"QualifierName": ["metabolism"], "DescriptorName": "Proto-Oncogene Proteins c-myc"}, {"QualifierName": ["metabolism"], "DescriptorName": "Receptors, Androgen"}, {"QualifierName": ["metabolism"], "DescriptorName": "Retinoblastoma Binding Proteins"}, {"QualifierName": [], "DescriptorName": "Signal Transduction"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}, {"QualifierName": ["classification", "diagnosis", "genetics"], "DescriptorName": "Triple Negative Breast Neoplasms"}, {"QualifierName": ["metabolism"], "DescriptorName": "Tumor Suppressor Protein p53"}, {"QualifierName": ["metabolism"], "DescriptorName": "Ubiquitin-Protein Ligases"}, {"QualifierName": ["metabolism"], "DescriptorName": "Wnt Proteins"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Prat A, et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. The oncologist. 2013;18:123\u2013133. doi: 10.1634/theoncologist.2012-0397.", "ArticleIdList": ["10.1634/theoncologist.2012-0397", "PMC3579595", "23404817"]}, {"Citation": "Prat A, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68. doi: 10.1186/bcr2635.", "ArticleIdList": ["10.1186/bcr2635", "PMC3096954", "20813035"]}, {"Citation": "Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u20132767. doi: 10.1172/JCI45014.", "ArticleIdList": ["10.1172/JCI45014", "PMC3127435", "21633166"]}, {"Citation": "Millikan RC, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109:123\u2013139. doi: 10.1007/s10549-007-9632-6.", "ArticleIdList": ["10.1007/s10549-007-9632-6", "PMC2443103", "17578664"]}, {"Citation": "Stark A, et al. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer. 2010;116:4926\u20134932. doi: 10.1002/cncr.25276.", "ArticleIdList": ["10.1002/cncr.25276", "PMC3138711", "20629078"]}, {"Citation": "Lehmann BD, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016;11:e0157368. doi: 10.1371/journal.pone.0157368.", "ArticleIdList": ["10.1371/journal.pone.0157368", "PMC4911051", "27310713"]}, {"Citation": "Golubnitschaja O, et al. Multi-omic approach decodes paradoxes of the triple-negative breast cancer: lessons for predictive, preventive and personalised medicine. Amino Acids. 2018;50:383\u2013395. doi: 10.1007/s00726-017-2524-0.", "ArticleIdList": ["10.1007/s00726-017-2524-0", "29249020"]}, {"Citation": "Schmid Peter, Adams Sylvia, Rugo Hope S., Schneeweiss Andreas, Barrios Carlos H., Iwata Hiroji, Di\u00e9ras V\u00e9ronique, Hegg Roberto, Im Seock-Ah, Shaw Wright Gail, Henschel Volkmar, Molinero Luciana, Chui Stephen Y., Funke Roel, Husain Amreen, Winer Eric P., Loi Sherene, Emens Leisha A. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2018;379(22):2108\u20132121. doi: 10.1056/NEJMoa1809615.", "ArticleIdList": ["10.1056/NEJMoa1809615", "30345906"]}, {"Citation": "Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative. Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019;9:176\u2013198. doi: 10.1158/2159-8290.CD-18-1177.", "ArticleIdList": ["10.1158/2159-8290.CD-18-1177", "PMC6387871", "30679171"]}, {"Citation": "Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25:5846\u20135853. doi: 10.1038/sj.onc.1209876.", "ArticleIdList": ["10.1038/sj.onc.1209876", "16998499"]}, {"Citation": "Jung J, et al. Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients. Curr Oncol. 2016;23:298\u2013303. doi: 10.3747/co.23.3054.", "ArticleIdList": ["10.3747/co.23.3054", "PMC5081005", "27803593"]}, {"Citation": "Lim E, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009;15:907\u2013913. doi: 10.1038/nm.2000.", "ArticleIdList": ["10.1038/nm.2000", "19648928"]}, {"Citation": "Turner N, Tutt A, Ashworth A. Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Cancer. 2004;4:814\u2013819. doi: 10.1038/nrc1457.", "ArticleIdList": ["10.1038/nrc1457", "15510162"]}, {"Citation": "Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Clin Pharmacokinet. 2018;57:427\u2013437. doi: 10.1007/s40262-017-0587-4.", "ArticleIdList": ["10.1007/s40262-017-0587-4", "29063517"]}, {"Citation": "Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med. 2015;66:455\u2013470. doi: 10.1146/annurev-med-050913-022545.", "ArticleIdList": ["10.1146/annurev-med-050913-022545", "25341009"]}, {"Citation": "Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346\u2013352. doi: 10.1038/nature10983.", "ArticleIdList": ["10.1038/nature10983", "PMC3440846", "22522925"]}, {"Citation": "Koboldt DC, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370. doi: 10.1038/nature11412.", "ArticleIdList": ["10.1038/nature11412", "PMC3465532", "23000897"]}, {"Citation": "Nik-Zainal S, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47\u201354. doi: 10.1038/nature17676.", "ArticleIdList": ["10.1038/nature17676", "PMC4910866", "27135926"]}, {"Citation": "Jones RA, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Invest. 2016;126:3739\u20133757. doi: 10.1172/JCI81568.", "ArticleIdList": ["10.1172/JCI81568", "PMC5096803", "27571409"]}, {"Citation": "Robinson Dan R., Wu Yi-Mi, Lonigro Robert J., Vats Pankaj, Cobain Erin, Everett Jessica, Cao Xuhong, Rabban Erica, Kumar-Sinha Chandan, Raymond Victoria, Schuetze Scott, Alva Ajjai, Siddiqui Javed, Chugh Rashmi, Worden Francis, Zalupski Mark M., Innis Jeffrey, Mody Rajen J., Tomlins Scott A., Lucas David, Baker Laurence H., Ramnath Nithya, Schott Ann F., Hayes Daniel F., Vijai Joseph, Offit Kenneth, Stoffel Elena M., Roberts J. Scott, Smith David C., Kunju Lakshmi P., Talpaz Moshe, Cie\u015blik Marcin, Chinnaiyan Arul M. Integrative clinical genomics of metastatic cancer. Nature. 2017;548(7667):297\u2013303. doi: 10.1038/nature23306.", "ArticleIdList": ["10.1038/nature23306", "PMC5995337", "28783718"]}, {"Citation": "Wang, S. et al. microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer. JCI Insight2, 10.1172/jci.insight.93313 (2017).", "ArticleIdList": ["PMC5543917", "28768903"]}, {"Citation": "Rueda OM, et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019;567:399\u2013404. doi: 10.1038/s41586-019-1007-8.", "ArticleIdList": ["10.1038/s41586-019-1007-8", "PMC6647838", "30867590"]}, {"Citation": "Wang DY, Gendoo DMA, Ben-David Y, Woodgett JR, Zacksenhaus E. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. Breast Cancer Res. 2019;21:18. doi: 10.1186/s13058-019-1098-z.", "ArticleIdList": ["10.1186/s13058-019-1098-z", "PMC6357448", "30704524"]}, {"Citation": "Liu JC, et al. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer. Cell Rep. 2018;23:112\u2013126. doi: 10.1016/j.celrep.2018.03.039.", "ArticleIdList": ["10.1016/j.celrep.2018.03.039", "29617654"]}, {"Citation": "Andrechek ER, et al. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci USA. 2009;106:16387\u201316392. doi: 10.1073/pnas.0901250106.", "ArticleIdList": ["10.1073/pnas.0901250106", "PMC2752567", "19805309"]}, {"Citation": "Gatza ML, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA. 2010;107:6994\u20136999. doi: 10.1073/pnas.0912708107.", "ArticleIdList": ["10.1073/pnas.0912708107", "PMC2872436", "20335537"]}, {"Citation": "Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370. doi: 10.1038/nature11412.", "ArticleIdList": ["10.1038/nature11412", "PMC3465532", "23000897"]}, {"Citation": "Choucair KA, et al. The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. Transl Oncol. 2012;5:453\u2013460. doi: 10.1593/tlo.12286.", "ArticleIdList": ["10.1593/tlo.12286", "PMC3568696", "23401739"]}, {"Citation": "Casey SC, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227\u2013231. doi: 10.1126/science.aac9935.", "ArticleIdList": ["10.1126/science.aac9935", "PMC4940030", "26966191"]}, {"Citation": "Liu JC, et al. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol Med. 2014;6:1542\u20131560. doi: 10.15252/emmm.201404402.", "ArticleIdList": ["10.15252/emmm.201404402", "PMC4287974", "25330770"]}, {"Citation": "Jiang Z, et al. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest. 2010;120:3296\u20133309. doi: 10.1172/JCI41490.", "ArticleIdList": ["10.1172/JCI41490", "PMC2929714", "20679727"]}, {"Citation": "Wang S, Liu JC, Kim D, Datti A, Zacksenhaus E. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer. Breast Cancer Res. 2016;18:9. doi: 10.1186/s13058-015-0668-y.", "ArticleIdList": ["10.1186/s13058-015-0668-y", "PMC4717616", "26781438"]}, {"Citation": "Knudsen ES, Zacksenhaus E. The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle control. Oncotarget. 2018;9:30940\u201330941. doi: 10.18632/oncotarget.25797.", "ArticleIdList": ["10.18632/oncotarget.25797", "PMC6089558", "30123416"]}, {"Citation": "Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol. 2001;21:2203\u20132212. doi: 10.1128/MCB.21.6.2203-2212.2001.", "ArticleIdList": ["10.1128/MCB.21.6.2203-2212.2001", "PMC86854", "11238953"]}, {"Citation": "Blanco-Aparicio C, et al. Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One. 2010;5:e9305. doi: 10.1371/journal.pone.0009305.", "ArticleIdList": ["10.1371/journal.pone.0009305", "PMC2824815", "20174572"]}, {"Citation": "Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2018;175:313\u2013326. doi: 10.1016/j.cell.2018.09.035.", "ArticleIdList": ["10.1016/j.cell.2018.09.035", "PMC6538253", "30290139"]}, {"Citation": "Wellenstein MD, de Visser KE. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. Immunity. 2018;48:399\u2013416. doi: 10.1016/j.immuni.2018.03.004.", "ArticleIdList": ["10.1016/j.immuni.2018.03.004", "29562192"]}, {"Citation": "Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48:434\u2013452. doi: 10.1016/j.immuni.2018.03.014.", "ArticleIdList": ["10.1016/j.immuni.2018.03.014", "PMC7116507", "29562194"]}, {"Citation": "Sun S, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer immunology, immunotherapy: CII. 2014;63:395\u2013406. doi: 10.1007/s00262-014-1519-x.", "ArticleIdList": ["10.1007/s00262-014-1519-x", "24514954"]}, {"Citation": "Gruosso T, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019;129:1785\u20131800. doi: 10.1172/JCI96313.", "ArticleIdList": ["10.1172/JCI96313", "PMC6436884", "30753167"]}, {"Citation": "Mariathasan S, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u2013548. doi: 10.1038/nature25501.", "ArticleIdList": ["10.1038/nature25501", "PMC6028240", "29443960"]}, {"Citation": "Tauriello DVF, et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538\u2013543. doi: 10.1038/nature25492.", "ArticleIdList": ["10.1038/nature25492", "29443964"]}, {"Citation": "Dvinge H, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497:378\u2013382. doi: 10.1038/nature12108.", "ArticleIdList": ["10.1038/nature12108", "23644459"]}, {"Citation": "Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun7, 10.1038/ncomms11479 (2016).", "ArticleIdList": ["PMC4866047", "27161491"]}, {"Citation": "Buffa FM, et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 2011;71:5635\u20135645. doi: 10.1158/0008-5472.CAN-11-0489.", "ArticleIdList": ["10.1158/0008-5472.CAN-11-0489", "21737487"]}]}], "History": [{"Year": "2019", "Month": "8", "Day": "7"}, {"Year": "2019", "Month": "12", "Day": "2"}, {"Year": "2019", "Month": "12", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "12", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "12", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "12", "Day": "13"}], "PublicationStatus": "epublish", "ArticleIdList": ["31836816", "PMC6911070", "10.1038/s41598-019-55710-w", "10.1038/s41598-019-55710-w"]}}]}